These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 15737773

  • 1. Safety and immunogenicity of concomitant versus nonconcomitant administration of hepatitis B, tetanus-diphtheria, and measles-mumps-rubella vaccines in healthy eleven- to twelve-year-olds.
    Cassidy WM, Jones G, Williams K, Deforest A, Forghani B, Virella G, Venters C.
    J Adolesc Health; 2005 Mar; 36(3):187-92. PubMed ID: 15737773
    [Abstract] [Full Text] [Related]

  • 2. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines.
    Shinefield H, Black S, Thear M, Coury D, Reisinger K, Rothstein E, Xu J, Hartzel J, Evans B, Digilio L, Schödel F, Brown ML, Kuter B, 013 Study Group for ProQuad.
    Pediatr Infect Dis J; 2006 Apr; 25(4):287-92. PubMed ID: 16567978
    [Abstract] [Full Text] [Related]

  • 3. Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 years.
    Black S, Friedland LR, Schuind A, Howe B, GlaxoSmithKline DTaP-IPV Vaccine Study Group.
    Vaccine; 2006 Aug 28; 24(35-36):6163-71. PubMed ID: 16759769
    [Abstract] [Full Text] [Related]

  • 4. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.
    Zignol M, Peracchi M, Tridello G, Pillon M, Fregonese F, D'Elia R, Zanesco L, Cesaro S.
    Cancer; 2004 Aug 01; 101(3):635-41. PubMed ID: 15274078
    [Abstract] [Full Text] [Related]

  • 5. Immunogenicity and safety of a combined hepatitis A and B vaccine administered concomitantly with either a measles-mumps-rubella or a diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis vaccine mixed with a Haemophilus influenzae type b conjugate vaccine in infants aged 12-18 months.
    Usonis V, Meriste S, Bakasenas V, Lutsar I, Collard F, Stoffel M, Tornieporth N.
    Vaccine; 2005 Apr 08; 23(20):2602-6. PubMed ID: 15780442
    [Abstract] [Full Text] [Related]

  • 6. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
    Nolan T, Bernstein DI, Block SL, Hilty M, Keyserling HL, Marchant C, Marshall H, Richmond P, Yogev R, Cordova J, Cho I, Mendelman PM, LAIV Study Group.
    Pediatrics; 2008 Mar 08; 121(3):508-16. PubMed ID: 18310199
    [Abstract] [Full Text] [Related]

  • 7. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P, Lim FS, Han HH, Willems P.
    Infection; 2007 Oct 08; 35(5):326-33. PubMed ID: 17710370
    [Abstract] [Full Text] [Related]

  • 8. Immunogenicity and safety of a varicella vaccine, Okavax, and a trivalent measles, mumps and rubella vaccine, MMR-II, administered concomitantly in healthy Filipino children aged 12-24 months.
    Gatchalian S, Leboulleux D, Desauziers E, Bermal N, Borja-Tabora C.
    Southeast Asian J Trop Med Public Health; 2003 Sep 08; 34(3):589-97. PubMed ID: 15115135
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine.
    Black SB, Cimino CO, Hansen J, Lewis E, Ray P, Corsaro B, Graepel J, Laufer D.
    Pediatr Infect Dis J; 2006 Apr 08; 25(4):306-11. PubMed ID: 16567981
    [Abstract] [Full Text] [Related]

  • 10. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T, Baer M, Willems P.
    Pediatr Infect Dis J; 2007 Feb 08; 26(2):153-8. PubMed ID: 17259879
    [Abstract] [Full Text] [Related]

  • 11. Simultaneous vaccination of Chinese applicants for a United States immigrant visa.
    Hua L, Hongtao H, Shunqin W, Jinping G, Jiandong C, Zhaoliang L, Xinwen F.
    Travel Med Infect Dis; 2008 May 08; 6(3):130-6. PubMed ID: 18486068
    [Abstract] [Full Text] [Related]

  • 12. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y, Steri GC, Behre U, Arsène JP, Lanse X, Helm K, Esposito S, Meister N, Desole MG, Douha M, Willems P.
    Vaccine; 2009 Jan 14; 27(3):446-53. PubMed ID: 19007835
    [Abstract] [Full Text] [Related]

  • 13. Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial.
    Dagan R, Amir J, Livni G, Greenberg D, Abu-Abed J, Guy L, Ashkenazi S, Foresner G, Tewald F, Schätzl HM, Hoffmann D, Ibanez R, Herzog C.
    Pediatr Infect Dis J; 2007 Sep 14; 26(9):787-93. PubMed ID: 17721372
    [Abstract] [Full Text] [Related]

  • 14. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM, Williams WR, Miller JM, Black S, Shinefield H, Henderson F, Marchant CD, Werzberger A, Halperin S, Hartzel J, Klopfer S, Schödel F, Kuter BJ, Consistency Lot Study Group for ProQuad.
    Pediatr Infect Dis J; 2006 Jul 14; 25(7):615-22. PubMed ID: 16804432
    [Abstract] [Full Text] [Related]

  • 15. Concomitant administration of a bivalent Haemophilus influenzae type b-hepatitis B vaccine, measles-mumps-rubella vaccine and varicella vaccine: safety, tolerability and immunogenicity.
    Hesley TM, Reisinger KS, Sullivan BJ, Jensen EH, Stasiorowski S, Meechan C, Chan CY, West DJ, HIB-HB VACCINE STUDY GROUP.
    Pediatr Infect Dis J; 2004 Mar 14; 23(3):240-5. PubMed ID: 15014300
    [Abstract] [Full Text] [Related]

  • 16. Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children.
    Guerra FA, Gress J, Werzberger A, Reisinger K, Walter E, Lakkis H, Grosso AD, Welebob C, Kuter BJ, Pediatric Study Group for VAQTA.
    Pediatr Infect Dis J; 2006 Oct 14; 25(10):912-9. PubMed ID: 17006287
    [Abstract] [Full Text] [Related]

  • 17. Are we hitting immunity targets? The 2006 age-specific seroprevalence of measles, mumps, rubella, diphtheria and tetanus in Belgium.
    Theeten H, Hutse V, Hens N, Yavuz Y, Hoppenbrouwers K, Beutels P, Vranckx R, Van Damme P.
    Epidemiol Infect; 2011 Apr 14; 139(4):494-504. PubMed ID: 20587123
    [Abstract] [Full Text] [Related]

  • 18. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
    Halperin SA, Ferrera G, Scheifele D, Predy G, Stella G, Cuccia M, Douha M, Willems P.
    Vaccine; 2009 May 05; 27(20):2701-6. PubMed ID: 19428882
    [Abstract] [Full Text] [Related]

  • 19. Immunogenicity and safety of a varicella vaccine (Okavax) and a trivalent measles, mumps, and rubella vaccine (Trimovax) administered concomitantly in healthy Filipino children 12-24 months old.
    Gatchalian S, Tabora C, Bermal N, Leboulleux D, Desauziers E.
    Am J Trop Med Hyg; 2004 Mar 05; 70(3):273-7. PubMed ID: 15031516
    [Abstract] [Full Text] [Related]

  • 20. Adult immunization.
    Treat Guidel Med Lett; 2006 Jul 05; 4(47):47-54. PubMed ID: 16785849
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.